as a result of a retrospective therapy study in an at least one-year therapy with cytostatics , thrombocyte aggregation inhibitors and anticoagulants ( caa-therapy , n = 27 ) , additional prednisone therapy ( caap-therapy , n = 95 ) and cytostatic-prednisone therapy ( cp-therapy , n = 33 ) we find favourable results for the caa/caap-therapy in the nephrotic syndrome and glomerulonephritides with distinct clinical exacerbation also in sclerosations in histology .
C0032952
prednisone
C0027726
nephrotic syndrome